---
title: "Goldman Sachs lowers UNITED LAB sales and profit forecasts, target price raised to 16.07 yuan"
description: "Goldman Sachs lowered UNITED LAB's sales forecast for 2023 to 2027 by 17.7% to 17.8%, and profit forecast by 28.4% to 35.6%. It is expected that the prices of active pharmaceutical ingredients for ant"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255710490.md"
published_at: "2025-09-03T03:50:30.000Z"
---

# Goldman Sachs lowers UNITED LAB sales and profit forecasts, target price raised to 16.07 yuan

> Goldman Sachs lowered UNITED LAB's sales forecast for 2023 to 2027 by 17.7% to 17.8%, and profit forecast by 28.4% to 35.6%. It is expected that the prices of active pharmaceutical ingredients for antibiotics will be weak in the next two years, but the sales forecast for insulin products has been raised by 27% to 30%. The target price has been raised from 15.29 yuan to 16.07 yuan, with a rating of "Neutral." Sales in the first half of the year increased by 5% year-on-year to 7.5 billion yuan, while core business revenue decreased by 15% year-on-year to 6.1 billion yuan, which was below expectations, and profit increased by 27% year-on-year to 1.9 billion yuan

Goldman Sachs lowered the sales forecast for UNITED LAB (03933.HK) for this year to 2027 by 17.7% to 17.8%, and the profit forecast was cut by 28.4% to 35.6%. It is expected that the price cycle for active pharmaceutical ingredients for antibiotics will be weak in the next two years, while the sales forecast for high-margin insulin products has been raised by 27% to 30%, benefiting from incremental sales brought by exports.

The firm raised its target price for the stock from HKD 15.29 to HKD 16.07, maintaining a "Neutral" rating. The firm indicated that the company's sales in the first half of the year increased by 5% year-on-year to RMB 7.5 billion, while core business revenue fell by 15% year-on-year to RMB 6.1 billion, which was below the firm's expectation of RMB 6.5 billion. Profit increased by 27% year-on-year to RMB 1.9 billion, but core profit declined and was below the firm's expectations. The firm noted that the gross margin of intermediates and bulk pharmaceuticals was eroded, and increased administrative expenses due to business expansion consulting fees

### Related Stocks

- [03933.HK - UNITED LAB](https://longbridge.com/en/quote/03933.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| TUL Roxithromycin Capsules Gain China Consistency Evaluation Approval | The United Laboratories International Holdings Limited (TUL) announced that its subsidiary has received approval from th | [Link](https://longbridge.com/en/news/275299526.md) |
| IRS improperly disclosed confidential immigrant tax data to DHS, Washington Post reports | WASHINGTON, Feb 11 (Reuters) - The Internal Revenue Service improperly disclosed confidential tax information of thousan | [Link](https://longbridge.com/en/news/275629445.md) |
| Dekon Food And Agriculture Group Held Extraordinary General Meeting | Dekon Food And Agriculture Group held an extraordinary general meeting on February 11, 2026, where shareholders approved | [Link](https://longbridge.com/en/news/275592083.md) |
| GRAINS-Chicago soybeans extend rally on China buying hopes | Chicago soybean futures rose to a two-month high, driven by expectations of increased demand from China for U.S. supplie | [Link](https://longbridge.com/en/news/275840226.md) |
| 'Swift Home' trademark abandoned after Taylor Swift opposition | A bedding company, Cathay Home Inc, has abandoned its application for a federal "Swift Home" trademark after Taylor Swif | [Link](https://longbridge.com/en/news/275955667.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
